Actively Recruiting
Phase 2 Trial of Radiation Therapy to Boost Elranatamab in Relapsed Refractory Multiple Myeloma with Extramedullary and Paramedullary Disease
Led by M.D. Anderson Cancer Center · Updated on 2026-09-18
34
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to find out if low doses of radiation therapy can help the drug elranatamab better kill cancer cells in people with relapsed refractory multiple myeloma RRMM who also have extramedullary or paramedullary disease. The study focuses on measuring the overall response rate after 3 months and also tracks safety, side effects, and quality of life among participants. It is a phase 2 trial conducted to improve treatment outcomes in this specific group of cancer patients. Participants will receive elranatamab given by intravenous IV infusion combined with radiation therapy targeted at lesions not previously treated with radiation. The study evaluates how radiation might stimulate the immune system to enhance the effect of elranatamab. Radiation is aimed at specific disease sites identified on PETCT or MRI scans, and supportive care such as transfusions or growth factors is allowed as needed. During the trial, participants will be closely monitored for safety and adverse events through regular assessments. Researchers will evaluate response to treatment, time until next treatment, progression-free survival, overall survival, and control of irradiated lesions. Quality of life will also be measured. Participation includes imaging, blood tests, and clinical evaluations over about one year, with ongoing safety monitoring throughout the study period.
CONDITIONS
Brief Title
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
Research Team
C
Christine Ye, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here